Clinical Trial: Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation

U.S., Feb. 5 -- ClinicalTrials.gov registry received information related to the study (NCT06807606) titled 'Optimized Cord Blood Transplantation for the Treatment of Patients With High-risk Hematologic Malignancies Who Have Relapsed After First Allogeneic Stem Cell Transplantation' on Jan. 29.

Brief Summary: The goal of this clinical research study is to learn if intermediate-intensity conditioning therapy followed by a cord blood transplant can help to control high-risk hematological malignancies in patients who need a second allogeneic stem cell transplantation.

Study Start Date: June 30, 2025

Study Type: INTERVENTIONAL

Condition: Hematologic Malignancies

Intervention: DRUG: Drugs Cyclophosphamide

Given as standard of care treatme...